Login to Your Account



Spectrum, TopoTarget Enter $350M Deal for Belinostat

By Catherine Hollingsworth


Wednesday, February 3, 2010
Spectrum Pharmaceuticals has entered a co-development and commercialization agreement with TopoTarget A/S for belinostat, a histone deacetylase (HDAC) inhibitor, a deal worth a potential $350 million plus royalties on any net sales. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription